Humana Says Exploring All Available Options To Mitigate Expected 2026 Revenue Headwind Related To Its 2025 Star Ratings In The Event Its Challenges To Results Are Unsuccessful - FIling
Humana Says Exploring All Available Options To Mitigate Expected 2026 Revenue Headwind Related To Its 2025 Star Ratings In The Event Its Challenges To Results Are Unsuccessful - FIling
Based on preliminary 2025 Medicare Advantage (MA) Star Ratings data provided by the Centers for Medicare and Medicaid Services (CMS), which became available in CMS Plan Finder as of October 1, 2024, Humana Ihas approximately 1.6 million, or 25%, of its members currently enrolled in plans rated 4 stars and above for 2025, a reduction from 94% in 2024.
根據康哲藥業提供的初步2025年醫療保險優惠(MA)星級評定數據，這些數據自2024年10月1日起可以在CMS計劃搜索器中查看，目前有大約160萬名哈門那會員參加了2025年評定爲4顆星及以上的計劃，這佔其25%的會員，較2024年的94%有所降低。
A significant driver of these results was contract H5216 decreasing to a 3.5-star rating from a 4.5-star rating in 2024. The decline in Stars performance for 2025 will impact Humana's quality bonus payments in 2026. 2025 Star rating details are expected to be formally released by CMS on or around October 10th.
造成這些結果的一個重要驅動因素是，合同H5216的評級從2024年的4.5顆星下降爲3.5顆星。2025年的星級表現下降將會影響到哈門那在2026年的品質獎金支付。CMS預計將在2025年10月10日前後正式發佈2025年星級評定詳細信息。
譯文內容由第三人軟體翻譯。